Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Global Nano Bioreactor Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on 12% CAGR with Leading Players Thermo Fisher Scientific, Danaher, Lonza, Cytiva and Sartorius

Thermo Fisher Scientific Inc.

Dublin, Oct. 21, 2026 -- "Nano Bioreactor Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global nano bioreactor market is experiencing rapid growth, driven by expanding biotechnology research, increased adoption of microfluidic bioprocessing, and demand for highly controlled, small-scale cell culture systems. The market is projected to grow from $4.64 billion in 2025 to $5.21 billion in 2026, representing a compound annual growth rate (CAGR) of 12.3%.

Growth during the historical period has been supported by rising investment in nanoscale biological research, greater use of miniaturized cell culture platforms, and an increasing focus on high-precision biomolecule production. The expansion of advanced biotechnology programs has also encouraged pharmaceutical companies, research institutions, and biotechnology developers to adopt nano bioreactors for efficient process development and experimentation.

Looking ahead, the nano bioreactor market is forecast to reach $8.19 billion by 2030, expanding at a CAGR of 12%. Key market trends include advances in nanobioprocessing, microfluidic lab-on-chip platforms, nanoscale cell culture engineering, automated nanosystems, and nanoscale enzymatic reaction technologies. These innovations are expected to improve process control, reduce reagent requirements, and accelerate the transition from laboratory research to larger-scale biopharmaceutical production.

The increasing demand for gene therapies is a major driver of nano bioreactor market growth. Advances in genetic sequencing and diagnostics are enabling researchers to identify disease-associated genes with greater precision and develop more targeted therapeutic approaches. Nano bioreactors support this work by providing tightly controlled cell culture conditions that can improve gene delivery, expression, cell viability, scalability, and process consistency.

Gene therapy development continues to gain momentum as regulatory approvals increase. According to the American Society of Gene & Cell Therapy, the US Food and Drug Administration approved six gene therapy products in 2023, compared with five in 2022. This expanding pipeline is creating demand for advanced bioprocessing technologies capable of supporting research, testing, optimization, and production workflows.

Personalized medicine is another important growth catalyst for the nano bioreactor industry. Advances in genomic technologies are helping developers identify individual genetic variations and create more targeted therapies. Nano bioreactors enable precise, small-scale cultivation and analysis of patient-specific cells and biomolecules, supporting customized drug testing, dose optimization, and individualized therapeutic development.

The Personalized Medicine Coalition reported that the US Food and Drug Administration approved 26 new personalized medicines in 2023, up significantly from 12 approvals in 2022. The continued expansion of personalized treatment pipelines is expected to strengthen demand for flexible, accurate, and resource-efficient nano bioreactor platforms.

Product innovation is also reshaping the competitive landscape. Market participants are developing miniaturized fixed-bed bioreactor systems designed to support cost-efficient and scalable cell culture process development. In October 2024, Belgium-based Univercells Technologies by Donaldson launched the scale-X nexo bioreactor. The platform offers a 0.5-square-meter growth surface and supports applications across cell and gene therapies, vaccines, and other advanced modalities.

The scale-X nexo system is designed to enable direct scalability to larger platforms within the same product family, helping developers transition from laboratory-stage work to commercial production while limiting process redevelopment. Its low-volume approach and integration with vision-based software for non-invasive cell counting can reduce media consumption, seed-train requirements, and operating costs for biotechnology and biopharmaceutical organizations.

Nano bioreactor applications span drug discovery, regenerative medicine, synthetic biology, diagnostics, vaccine production, recombinant proteins, monoclonal antibodies, biocatalysis, environmental monitoring, and basic research. Growing adoption across pharmaceutical companies, biotechnology businesses, academic institutions, research laboratories, contract manufacturing organizations, and environmental agencies is expected to broaden the market's commercial potential.

North America was the largest nano bioreactor market in 2025, supported by its established biopharmaceutical sector, advanced research infrastructure, and strong investment in gene and cell therapies. Asia-Pacific is expected to be the fastest-growing region during the forecast period as biotechnology manufacturing, research activity, and healthcare investment expand. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, including Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Russia, South Korea, Spain, Taiwan, the United Kingdom, and the United States.

Markets Covered:

  1. By Product Type: Nano-Scale Bioreactor Units; Microfluidic Bioreactors; Nano Fermentation Systems; Nanoscale Cell Culture Devices; Nano Enzymatic Reaction Modules; Nano Bioprocessing Chips; Lab-On-A-Chip Bioreactors
  2. By Molecule: Monoclonal Antibodies; Vaccines; Recombinant Proteins; Stem Cells; Gene Therapy
  3. By Technology: Microfluidics Technology; Nanotechnology-Enabled Bioprocessing; Lab-On-Chip Technology; Automated Miniaturized Bioreactor Technology; High-Precision Reaction Monitoring Technology
  4. By Application: Drug Discovery And Development; Tissue Engineering And Regenerative Medicine; Synthetic Biology And Biofuel Research; Biocatalysis And Enzyme Engineering; Environmental Monitoring And Bioremediation; Diagnostics And Biosensing; Basic Life Science Research
  5. By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Diagnostic Laboratories; Contract Research And Manufacturing Organizations; Food And Agriculture Industries; Environmental Testing Agencies

Subsegments:

  1. By Nano-Scale Bioreactor Units: Disposable Nano Reactor Modules; Pre-Sterilized Nano Cartridges; Compact Single-Cycle Units; High-Density Nano Culture Chambers; Plug-And-Play Nano Systems
  2. By Microfluidic Bioreactors: Integrated Channel Microfluidic Units; Perfusion-Based Microfluidic Systems; Droplet-Based Microfluidic Modules; High-Throughput Microfluidic Arrays; Automated Microfluidic Platforms
  3. By Nano Fermentation Systems: Continuous Nano Fermentation Units; Batch Nano Fermentation Chambers; Modular Nano Fermentation Platforms; High-Efficiency Nano Fermenters; Temperature-Controlled Nano Fermentation Units
  4. By Nanoscale Cell Culture Devices: Micro-Well Nanoscale Culture Plates; Three-Dimensional Nano Culture Scaffolds; Perfused Nanoscale Culture Modules; High-Density Nano Culture Chambers; Disposable Nanoscale Culture Units
  5. By Nano Enzymatic Reaction Modules: Flow-Through Nano Enzyme Reactors; Batch Nano Enzymatic Reaction Units; Temperature-Regulated Nano Enzymatic Modules; High-Surface Area Nano Reaction Chambers; Integrated Nano Enzyme Platforms
  6. By Nano Bioprocessing Chips: Lab-Integrated Nano Processing Chips; Micro-Channel Nano Bioprocessing Modules; High-Throughput Nano Chip Platforms; Disposable Nano Bioprocessing Units; Automated Nano Chip Systems
  7. By Lab-On-A-Chip Bioreactors: Microfluidic Lab-On-A-Chip Units; Integrated Nano Reaction Chip Platforms; Disposable Lab-On-A-Chip Modules; High-Throughput Lab-On-A-Chip Systems; Automated Lab-On-A-Chip Platforms

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes

Report AttributeDetails
No. of Pages250
Forecast Period2026-2030
Estimated Market Value (USD) in 2026$5.21 Billion
Forecasted Market Value (USD) by 2030$8.19 Billion
Compound Annual Growth Rate12%
Regions CoveredGlobal

The companies featured in this Nano Bioreactor market report include:

  • Thermo Fisher Scientific Inc.
  • Danaher Corp.
  • GE Healthcare Technologies Inc.
  • Lonza Group
  • Cytiva Sweden AB
  • Sartorius AG
  • Getinge AB
  • Eppendorf SE
  • Pall Corporation
  • PBS Biotech Inc.
  • Applikon Biotechnology B.V. (Getinge AB)
  • Bioengineering AG
  • PARR Instrument Company
  • Infors AG
  • LAVAL LAB Inc.
  • Cellec Biotek AG
  • Sysbiotech GmbH
  • HiTec Zang GmbH
  • CerCell Co.
  • m2p-labs GmbH

For more information about this report visit https://www.researchandmarkets.com/r/whvhmz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. FinanceThermo Fisher Scientific Inc.Thermo Fisher Scientific Reports Third Quarter 2026 ResultsCompanies: Thermo Fisher Scientific Inc.Revenue Grew 9% Including 6% Organic Revenue Growth Grew GAAP Diluted EPS 9% and Adjusted EPS 15% Outstanding performance driven by proven growth strategy and PPI Business System WALTHAM, Mass., October 21, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today repo
  2. AIGlobal Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use SystemsCompanies: Thermo Fisher Scientific Inc.Danaher CorporationMerck KGaABoost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.
  3. Biotech & pharmaGlobal Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use SolutionsCompanies: Thermo Fisher Scientific Inc.Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.
  4. Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and LonzaCompanies: Thermo Fisher Scientific Inc.Boost ROI with integrated single-use bioreactors that reduce contamination, setup time, cleaning, footprint and operating costs while improving scalability.
  5. Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGRCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. Biotech & pharmaBioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the IndustryCompanies: Thermo Fisher Scientific Inc.Agilent TechnologiesDanaher Corporation"Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering.